Gregory Renza

Truist Securities | Healthcare

Gregory Renza is an analyst from Truist Securities specializing in the Healthcare sector. Ranked #1004 out of 4773 analysts, they have issued 66 stock ratings with a success rate of 84.38% and an average return of 27.94%.

Gregory Renza has a well-established track record, with 66 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 84.38% and an average return of 27.94%, underscoring their expertise and ability to identify winning opportunities for investors.

#1004

Out of 4773

66

Total Ratings

+84.38%

Success Rate

+27.94%

Average Return

Recent Ratings Analysis

IDYA

Aug 05, 2026

Target

$59.00

Current

$37.59

Performance

4.30%

Gregory Renza rated IDYA as Buy on Aug 05, 2026, setting a price target of 59. Shares have remained stable near 37.59, leaving the 59 target still in play.

AMGN

Aug 05, 2026

Target

$362.00

Current

$377.35

Performance

-7.47%

On Aug 05, 2026, AMGN was given a Hold rating by Gregory Renza, with a target price of 362. The rating provided protection from downside risk as the stock fell to 377.35.

JAZZ

Aug 04, 2026

Target

$264.00

Current

$245.80

Performance

-6.05%

JAZZ received a Buy rating from Gregory Renza on Aug 04, 2026, aiming for 264. The rating hasn’t played out as hoped, with the stock trading 6.05% below expectations.

REGN

Jul 31, 2026

Target

$772.00

Current

$781.49

Performance

2.47%

On Jul 31, 2026, Gregory Renza published a Buy outlook on REGN, with a target of 772. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 781.49.

AGIO

Jul 31, 2026

Target

$39.00

Current

$33.60

Performance

11.93%

Gregory Renza on Jul 31, 2026 assigned AGIO a Buy rating, with a price target of 39. The Buy call aligned well with market performance, producing a gain of 11.93%.

NRIX

Jul 10, 2026

Target

$34.00

Current

$25.10

Performance

8.85%

On Jul 10, 2026, Gregory Renza reaffirmed NRIX with a Buy rating, targeting 34. The recommendation was supported by strong follow-through as the stock rose from 25.1 to 25.1.

EXEL

Jul 07, 2026

Target

$56.00

Current

$56.12

Performance

-1.68%

EXEL was rated Hold by Gregory Renza on Jul 07, 2026, with a price objective of 56. Flat performance suggests the Hold view was reasonable.

ZYME

Jul 07, 2026

Target

$31.00

Current

$26.24

Performance

-1.80%

On Jul 07, 2026, Gregory Renza initiated coverage on ZYME with a Buy rating and target of 31. Neutral price movement of -1.80% leaves room for interpretation.

XNCR

Jul 07, 2026

Target

$27.00

Current

$24.41

Performance

55.78%

Gregory Renza issued a Buy recommendation for XNCR on Jul 07, 2026, price target set at 27. Investors following the Buy call captured upside momentum, with shares now at 24.41.

ONC

Jul 07, 2026

Target

$416.00

Current

$346.51

Performance

12.15%

On Jul 07, 2026, ONC was evaluated by Gregory Renza, who gave a Buy rating and target of 416. This case illustrates how a timely bullish rating can translate into tangible gains of 12.15%.

NUVB

Jul 07, 2026

Target

$13.00

Current

$6.07

Performance

7.05%

Gregory Renza rated NUVB as Buy on Jul 07, 2026, setting a price target of 13. The call has proven timely, with shares rising 7.05% toward the price target of 13.

GILD

Jul 07, 2026

Target

$156.00

Current

$143.72

Performance

5.40%

On Jul 07, 2026, GILD was given a Buy rating by Gregory Renza, with a target price of 156. The stock rallied 5.40% after the rating, narrowing the gap to the target of 156 and validating the bullish stance.

ABVX

Jul 02, 2026

Target

$155.00

Current

$118.64

Performance

-17.98%

ABVX received a Buy rating from Gregory Renza on Jul 02, 2026, aiming for 155. The rating hasn’t played out as hoped, with the stock trading 17.98% below expectations.

RVMD

Jun 30, 2026

Target

$210.00

Current

$203.77

Performance

8.80%

On Jun 30, 2026, Gregory Renza published a Buy outlook on RVMD, with a target of 210. Shares gained 8.80%, underscoring the accuracy of the bullish outlook toward 210.

VRDN

Jun 30, 2026

Target

$38.00

Current

$21.24

Performance

15.62%

Gregory Renza on Jun 30, 2026 assigned VRDN a Buy rating, with a price target of 38. The Buy call aligned well with market performance, producing a gain of 15.62%.

NUVL

Jun 10, 2026

Target

$124.00

Current

$123.96

Performance

0.49%

On Jun 10, 2026, Gregory Renza reaffirmed NUVL with a Hold rating, targeting 124. The neutral call matched muted market action of 0.49%.

FULC

Jun 02, 2026

Target

$4.00

Current

$3.80

Performance

—

FULC was rated Hold by Gregory Renza on Jun 02, 2026, with a price objective of 4. Flat performance suggests the Hold view was reasonable.

CGON

May 14, 2026

Target

$82.00

Current

$72.35

Performance

4.04%

On May 14, 2026, Gregory Renza initiated coverage on CGON with a Buy rating and target of 82. Neutral price movement of 4.04% leaves room for interpretation.

AAPG

Nov 24, 2025

Target

$51.00

Current

$16.10

Performance

-49.73%

Gregory Renza issued a Buy recommendation for AAPG on Nov 24, 2025, price target set at 51. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

CATX

Nov 24, 2025

Target

$12.00

Current

$2.81

Performance

29.49%

On Nov 24, 2025, CATX was evaluated by Gregory Renza, who gave a Buy rating and target of 12. This case illustrates how a timely bullish rating can translate into tangible gains of 29.49%.

MNKD

Nov 24, 2025

Target

$9.00

Current

$3.75

Performance

-26.90%

Gregory Renza rated MNKD as Buy on Nov 24, 2025, setting a price target of 9. The stock has underperformed, dropping 26.90% despite the bullish target of 9.

BCYC

Nov 24, 2025

Target

$10.00

Current

$3.86

Performance

-42.73%

On Nov 24, 2025, BCYC was given a Hold rating by Gregory Renza, with a target price of 10. The rating provided protection from downside risk as the stock fell to 3.86.

CRMD

Mar 26, 2025

Target

$12.00

Current

$7.83

Performance

9.29%

CRMD received a Outperform rating from Gregory Renza on Mar 26, 2025, aiming for 12. Momentum has favored the Buy call, with shares climbing from 7.825 to 7.825, rewarding those who trusted the recommendation.

VSTM

Mar 21, 2025

Target

$14.00

Current

$7.32

Performance

10.08%

On Mar 21, 2025, Gregory Renza published a Outperform outlook on VSTM, with a target of 14. Shares gained 10.08%, underscoring the accuracy of the bullish outlook toward 14.

INO

Mar 19, 2025

Target

$5.00

Current

$1.25

Performance

-36.22%

Gregory Renza on Mar 19, 2025 assigned INO a Sector Perform rating, with a price target of 5. The call successfully avoided chasing as shares lost 36.22%.

PCRX

Jan 14, 2025

Target

$18.00

Current

$25.36

Performance

23.41%

On Jan 14, 2025, Gregory Renza reaffirmed PCRX with a Sector Perform rating, targeting 18. Market strength beyond 25.36 went further than the conservative outlook suggested.

JSPR

Jan 09, 2025

Target

$48.00

Current

$0.66

Performance

—

JSPR was rated Outperform by Gregory Renza on Jan 09, 2025, with a price objective of 48. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

CDTX

Dec 13, 2024

Target

$34.00

Current

$221.38

Performance

867.57%

On Dec 13, 2024, Gregory Renza initiated coverage on CDTX with a Outperform rating and target of 34. The stock’s climb of 867.57% since the call highlights the foresight in the rating.

SPRB

Dec 11, 2024

Target

$1.50

Current

$53.70

Performance

66.70%

Gregory Renza issued a Sector Perform recommendation for SPRB on Dec 11, 2024, price target set at 1.5. A neutral call gave way to stronger-than-expected performance, closing in on 1.5.

VRCA

Oct 04, 2024

Target

$11.00

Current

$4.91

Performance

274.81%

On Oct 04, 2024, VRCA was evaluated by Gregory Renza, who gave a Outperform rating and target of 11. This case illustrates how a timely bullish rating can translate into tangible gains of 274.81%.

VIRX

Aug 15, 2024

Target

$4.00

Current

$0.01

Performance

-97.19%

Gregory Renza rated VIRX as Outperform on Aug 15, 2024, setting a price target of 4. The stock has underperformed, dropping 97.19% despite the bullish target of 4.

ATYR

Aug 14, 2024

Target

$16.00

Current

$0.43

Performance

-76.77%

On Aug 14, 2024, ATYR was given a Outperform rating by Gregory Renza, with a target price of 16. Despite the Buy call, shares fell from 0.4298 to 0.4298, challenging the optimistic stance.

MORF

Jul 26, 2024

Target

$57.00

Current

$56.99

Performance

0.78%

MORF received a Sector Perform rating from Gregory Renza on Jul 26, 2024, aiming for 57. Shares remained flat at 56.99, aligning with the neutral rating.

ACAD

Jun 25, 2024

Target

$29.00

Current

$27.83

Performance

78.40%

On Jun 25, 2024, Gregory Renza published a Outperform outlook on ACAD, with a target of 29. Shares gained 78.40%, underscoring the accuracy of the bullish outlook toward 29.

Frequency Asked Questions

Who is Gregory Renza?

Gregory Renza is an analyst from Truist Securities specializing in the Healthcare sector.

What is Gregory Renza's success rate?

Gregory Renza currently has a success rate of +84.38%.

How many ratings has Gregory Renza issued?

Gregory Renza has issued 66 stock ratings so far.

What is the average return of Gregory Renza's calls?

Their stock ratings have generated an average return of +27.94%.

What is Gregory Renza's ranking?

Gregory Renza is ranked #1004 out of 4773 analysts.

What types of ratings does Gregory Renza give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Gregory Renza?

You can follow Gregory Renza by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Gregory Renza?

Their latest rating was a Buy on IDYA issued on 2026-08-05.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep